Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

103.70 +1.19 (+1.16%)

Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9

...

53 54 Next >

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? ↗

October 24, 2026

Abbott's $7.4B free cash flow and 0.3x debt load contrast sharply with UnitedHealth's $16.1B free cash flow but higher leverage and government policy risk.

Via The Motley Fool

MarketBeat Week in Review – 10/19 - 10/23 ↗

October 24, 2026

A market sell-off spread beyond tech as oil prices surged and AI concerns grew. MarketBeat analysts recap the week's top stories on earnings, from Halliburton to Meta Platforms and General Motors.

Via MarketBeat

Topics Artificial Intelligence Economy

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Via MarketBeat

S&P 500 Unusual Volume Movers: Oct. 21, 2026 ↗

October 21, 2026

Via Chartmill

Topics Stocks

Abbott Laboratories (NYSE:ABT) Posts In-Line Q3 Results as Reaffirmed Guidance and Nutrition Separation Pressure Shares ↗

October 21, 2026

Via Chartmill

Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals ↗

October 12, 2026

Via Chartmill

Cologuard Is Working—So Why Isn’t Abbott Stock? ↗

October 22, 2026

Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.

Via MarketBeat

Abbott: 3 Key Takeaways for Long-Term Investors ↗

October 21, 2026

Pulsed field ablation and expanded cancer screening tools position the core business for accelerated growth beyond historical rates.

Via The Motley Fool

Topics Earnings

S&P 500 Top Movers: Oct. 21, 2026 US Session ↗

October 21, 2026

Via Chartmill

Topics Stocks

Abbott (ABT) Q3 2026 Earnings Call Transcript ↗

October 21, 2026

Abbott plans nutrition spinoff by end of 2027 amid strong Q3 growth.

Via The Motley Fool

Topics Earnings

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call ↗

October 21, 2026

Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent...

Via MarketBeat

Topics Earnings

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers ↗

October 21, 2026

Via Chartmill

Topics Stocks

Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations

October 21, 2026

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $...

Via StockStory

S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines ↗

October 21, 2026

Via Chartmill

Topics Artificial Intelligence Stocks Supply Chain

S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall ↗

October 20, 2026

Via Chartmill

Topics Stocks

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗

October 18, 2026

It was Griffin's biggest add for Citadel last quarter.

Via The Motley Fool

Topics Economy

I Just Invested $4,600 Across 3 Top Dividend Stocks. Here’s What I’m Loading Up on Right Now. ↗

October 17, 2026

These companies pay durable and growing dividends.

Via The Motley Fool

Topics Economy

Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle ↗

October 17, 2026

Rising rates can expose dividend traps, but this Dividend King is built to keep paying.

Via The Motley Fool

Topics Credit Cards

The Market Is Flashing Warning Signals Not Seen in Years. Here’s Why I Just Bought 3 of SCHD’s Dividend Kings. ↗

October 13, 2026

The market's warning signs are driving me to shift my portfolio towards high-quality holdings.

Via The Motley Fool

Topics ETFs Economy

Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell ↗

October 12, 2026

These companies have a long history of dividend growth.

Via The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 12, 2026

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

Via The Motley Fool

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway. ↗

October 11, 2026

A super-high yield isn't everything.

Via The Motley Fool

Topics Intellectual Property

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗

October 10, 2026

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Via The Motley Fool

Topics Intellectual Property

History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. ↗

October 10, 2026

Abbott has a low-risk profile with significant upside potential.

Via The Motley Fool

These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here's Why They Are Better Buys Anyway. ↗

October 01, 2026

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

Via The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 01, 2026

Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

Via The Motley Fool

Want a Portfolio That Pays You $1,000 a Month in Passive Income? This Dividend ETF Could Get You There. ↗

September 24, 2026

It's as stable and consistent as you'd hope from a dividend ETF.

Via The Motley Fool

Topics ETFs

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade ↗

September 24, 2026

It would be hard for investors to replicate the company's return over the past decade.

Via The Motley Fool

Topics Intellectual Property

3 High-Yielding Dividend Stocks That Are No-Brainer Buys for Retirees and Risk-Averse Investors ↗

September 22, 2026

These quality, low-volatility stocks yield between 2.4% and 3.1%, and have been raising their payouts for decades.

Via The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth ↗

September 21, 2026

Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.

Via The Motley Fool

Topics Product Recall

< Previous 1 2 3 4 5 6 7 8 9

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.